

UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 30TH SEPTEMBER, 2008

(Rs.in Lacs)

Sr.no	Particulars	3 months ended	Corresponding 3	9 Months Ended	Corresponding 9	For the Year
		30/09/2008	months ended	30/09/2008	Months Ended	30/09/2007
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income					
	a) Net Sales/Income from Operations	30,166.97	24,845.64	84,764.87	64,955.24	91,084.76
	b) Other Operating Income	198.23	253.19	767.08	732.87	995.84
	c) Total	30,365.20	25,098.83	85,531.95	65,688.11	92,080.60
2	Expenditure					
	a) Increase/decrease in stock in trade and work in progress	1,501.91	(2,917.64)	(535.17)	(6,164.21)	(5,746.29)
	b) Consumption of raw materials	9,016.47	11,656.22	29,819.07	28,402.98	37,352.61
	c) Employees Cost	875.06	563.86	2,578.29	1,500.64	2,437.42
	d) Depreciation	2,814.09	2,540.73	7,833.88	6,474.67	8,625.97
	e) Other expenditure	5,450.32	4,402.69	15,426.23	11,534.19	16,175.81
	f) Total	19,657.85	16,245.86	55,122.30	41,748.27	58,845.52
3	Profit from Operations before Other Income and Interest (1-2)	10,707.35	8,852.97	30,409.65	23,939.84	33,235.08
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit before Interest (3+4)	10,707.35	8,852.97	30,409.65	23,939.84	33,235.08
6	Interest	1,237.21	1,018.51	3,478.40	3,037.88	4,135.20
7	Profit (+) / Loss (-) from Ordinary Activities before tax (5-6)	9,470.14	7,834.46	26,931.25	20,901.96	29,099.88
8	Tax expense					
	a) Current	1,050.00	850.00	3,000.00	2,215.00	3,150.00
	b) Deffered	2,000.00	1,675.00	5,700.00	4,250.00	6,350.00
	c) Fringe Benefit	12.00	6.12	35.00	17.99	40.00
	d) Total	3,062.00	2,531.12	8,735.00	6,482.99	9,540.00
9	Net Profit (+)/Loss (-) from Ordinary Activities after tax (7-8)	6,408.14	5,303.34	18,196.25	14,418.97	19,559.88
10	Extraordinary Items	283.16	320.11	849.48	801.51	1,010.76
11	Net Profit (+)/Loss (-) for the period (9-10)	6,124.98	4,983.23	17,346.77	13,617.46	18,549.12
12	Prior year adjustment	0.00	0.00	0.00	0.00	178.59
13	Profit available for appropriation	6,124.98	4,983.23	17,346.77	13,617.46	18,370.53
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,397.58	2,289.02	2,397.58	2,289.02	2,294.76
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.					126,895.57
16	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	2.67	2.32	7.59	6.30	8.52
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	2.55	2.18	7.24	5.95	8.08
17	Public Shareholding					
	- Number of shares	123,228,193	123,433,867	123,228,193	123,433,867	124,007,515
	- Percentage of shareholding	51.40%	53.92%	51.40%	53.92%	54.04%

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above financial results were reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 24th October, 2008.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30th September, 2008
- 4 During the Quarter the Company has issued 5,736,503 equity shares of Re.1/- each pursuant to conversion of FCCBs.
- 5 The number of investor complaints for the quarter ended on 30th September, 2008 were : Openging - 3, Received - 20, Disposed off - 20. and Balance - 3.

For and on Behalf of
STERLING BIOTECH LIMITED

Place : Mumbai
Date : 24th October, 2008

Chetan J. Sandesara
Jt. Managing Director